-
Mashup Score: 1Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma Final Analysis of Ro-CHOP Trial - The ASCO Post - 1 month(s) ago
As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with peripheral T-cell lymphoma (PTCL). In the international open-label study, 421 patients were randomly assigned between January 2013 and December 2017 to receive Ro-CHOP (n = 211) or CHOP (n
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Mantle Cell Lymphoma: Front-Line Therapy - The ASCO Post - 1 month(s) ago
“The practice of medicine is an art, not a trade….” —Sir William Osler Mantle cell lymphoma (MCL) accounts for approximately 5% to 7% of all lymphomas; the median age of patients with MCL is between 60 and 70 years. This lymphoma is generally considered incurable. Median survival in retrospective studies from the late 1990s ranged from 3 to 5 years; this outcome has improved with intensive induction and maintenance rituximab, and a median survival of 10 or more years can now be expected for many younger
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission? - The ASCO Post - 2 month(s) ago
For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. 1 CAR T-cell therapy has become standard of care for relapsed LBCL as early as in the second line. But in this multivariate analysis of patient s who had a complete
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Should You Reconsider Transplant for Relapsed Large B-Cell Lymphoma in Complete Remission? - The ASCO Post - 2 month(s) ago
For patients with relapsed large B-cell lymphoma (LBCL) in complete remission, outcomes were better after autologous stem cell transplantation (ASCT) than with chimeric antigen receptor (CAR) T-cell therapy in a retrospective analysis of a large database presented at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition. 1 CAR T-cell therapy has become standard of care for relapsed LBCL as early as in the second line. But in this multivariate analysis of patient s who had a complete
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma Final Analysis of Ro-CHOP Trial - The ASCO Post - 2 month(s) ago
As reported in the Journal of Clinical Oncology by Camus et al, the final analysis of the phase III Ro-CHOP trial showed no significant progression-free or overall survival benefit with the addition of romidepsin (Ro) to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in previously untreated patients with peripheral T-cell lymphoma (PTCL). In the international open-label study, 421 patients were randomly assigned between January 2013 and December 2017 to receive Ro-CHOP (n = 211) or CHOP (n
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In a phase II trial (JACKPOT8 Part B) reported in The Lancet Oncology, Song et al found that the selective JAK1 tyrosine kinase inhibitor golidocitinib showed activity in patients with relapsed or refractory peripheral T-cell lymphoma. In the trial, 104 patients from sites in Australia, China, South Korea, and the United States who had received at least one previous line of systemic therapy were enrolled between February 2021 and October 2022; a total of 94% of patients were Asian. Patients received oral
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Rituximab Maintenance in Younger Patients With Mantle Cell Lymphoma Long-Term Follow-up - The ASCO Post - 4 month(s) ago
In a long-term analysis from the LYMA trial reported in the Journal of Clinical Oncology, Sarkozy et al found that rituximab maintenance following autologous stem cell transplantation (ASCT) continued to be of benefit vs observation in the first-line treatment of younger patients with mantle cell lymphoma. The analysis involved determination of long-term outcomes among 240 patients randomly assigned within 3 months after ASCT to receive rituximab maintenance (n = 120) or placebo (n = 120). Median
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy - The ASCO Post - 4 month(s) ago
In cases where DLBCL—the most prevalent form of non-Hodgkin lymphoma affectin g the lymphocytes—does not respond to initial therapy or recurs within 12 months posttreatment, the standard-care protocol typically includes platinum-based chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation. In 2022, the U.S. Food and Drug Administration granted approval to lisocabtagene maraleucel as a second-line treatment for patients with DLBCL. However, the cost effectiveness of
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Mantle Cell Lymphoma Predictive Value of Measurable Residual Disease With Rituximab Maintenance - The ASCO Post - 5 month(s) ago
In an analysis from the European Mantle Cell Lymphoma Elderly Trial reported in the Journal of Clinical Oncology, Hoster et al found that outcomes with rituximab maintenance were better in patients aged ≥ 60 years with mantle cell lymphoma who had measurable residual disease (MRD)-negative vs MRD-positive status after induction therapy. In the trial, 560 previously untreated patients were randomly assigned between January 2004 and October 2010 to rituximab vs interferon-alpha maintenance after response
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3CNS Prophylaxis With High-Dose Methotrexate in High-Risk Aggressive B-Cell Lymphoma - The ASCO Post - 5 month(s) ago
In a retrospective study reported in the Journal of Clinical Oncology, Lewis et al found that prophylactic high-dose methotrexate did not appear to offer a clinically meaningful reduction in risk of central nervous system (CNS) progression in patients with high-risk aggressive B-cell lymphoma. The study involved data collected between 2000 and 2020 at 23 sites in Australia, Asia, North America, and Europe from patients aged 18 to 80 years diagnosed with aggressive B-cell lymphoma who were at high risk of
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
Romidepsin Plus CHOP in Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of Ro-CHOP Trial https://t.co/I76QKcgAOQ #lymsm #lymphoma #hematology